Overview

Novel Desensitization Protocol for Highly Sensitized Patients to Allow for Successful Kidney Transplantation. A Pilot Study.

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Chicago

Treatments:

Abatacept
Proteasome Inhibitors